Benefits
Fasting blood sugar lowered in an open-label diabetes trial
In a randomized open-label trial in newly-diagnosed Type 2 diabetics with dyslipidemia, Saberry at 2 g/day was associated with a 21.8% lowering of fasting blood sugar vs 14.6% with 1 g/day. This trial was open-label (not blinded), manufacturer-affiliated (Sami-Sabinsa), and conducted in a diagnosed-disease population, so it reports an association rather than establishing that Saberry treats diabetes. Amla's better-controlled human evidence is for lipid and antioxidant support in non-diabetic and dyslipidemic adults.
Compared with metformin in an open-label manufacturer trial
The three-arm trial compared Saberry 1 g, Saberry 2 g, and metformin 500 mg. Numerically the 2 g dose showed a larger fasting-glucose fall than metformin 500 mg. Important limitations: the trial was open-label (not blinded), run by the manufacturer (Sami-Sabinsa), and conducted in people with diagnosed type 2 diabetes; metformin 500 mg is also the low end of therapeutic dosing (typical 1,000-2,000 mg). These design choices mean the data cannot establish that Saberry outperforms metformin, and a dietary supplement is not a treatment for diabetes.
Comprehensive lipid profile improvement
A separate double-blind, placebo-controlled trial in adults with dyslipidemia (Upadya 2019) reported reductions in total cholesterol, LDL, VLDL and triglycerides — the better-controlled lipid evidence for this extract. The lipid data in the open-label diabetes trial were comparable to metformin. These findings describe changes in blood-lipid markers, not a claim that the ingredient treats metabolic disease.
Post-prandial blood sugar reduction
The same open-label, manufacturer-affiliated trial in people with diagnosed type 2 diabetes reported improvement in post-prandial blood sugar (PPBS) alongside fasting blood sugar. Post-prandial glucose spikes are relevant to diabetic complications, but because these data come from a single unblinded trial in a disease population, they describe that study's findings rather than establishing that Saberry provides glycemic control or treats diabetes.
HbA1c reduction
The same open-label, manufacturer-affiliated trial reported a reduction in hemoglobin A1c (HbA1c) in people with diagnosed type 2 diabetes. HbA1c reflects average blood glucose over 2-3 months. Because this is a single unblinded trial in a disease population, it describes that study's result and is not evidence that Saberry prevents diabetes complications or should be used to manage diabetes.
Beta-glucogallin biomarker standardization
Saberry is the only Amla extract standardized to beta-glucogallin — a Gallotannin compound that holds the key to health benefits obtained from Indian Gooseberry. Distinguished from other Amla products standardized to phenols, generic tannins, or low-molecular-weight hydrolyzable tannins. The specific marker enables reproducible bioactivity.
Antioxidant and rejuvenative properties
Amla's antioxidant potential has been extensively studied — well-known for rejuvenative properties in traditional Ayurvedic medicine. Helps maintain anti-oxidant enzyme levels in the system. Widely used in digestive support and immune support applications. Traditional use spanning thousands of years in Ayurvedic medicine supports broad safety and tolerability.
Water-soluble functional beverage applications
Saberry's water-solubility and excellent taste profile make it uniquely suitable for functional beverages, smoothies, and RTD products — distinguished from many botanical extracts limited to capsules/tablets by taste or solubility issues. Self-affirmed GRAS supports formulation flexibility across food and beverage applications.
Mechanism of action
Beta-glucogallin bioactivity
Beta-glucogallin is a Gallotannin compound (gallic acid linked to glucose) with documented antioxidant, anti-inflammatory, and metabolic effects. Saberry's standardization to ≥10% beta-glucogallin ensures reproducible bioactivity. Beta-glucogallin has documented aldose reductase inhibition — relevant for diabetic complication prevention.
Aldose reductase inhibition
Aldose reductase converts glucose to sorbitol in the polyol pathway — driving diabetic complications including cataracts, neuropathy, and retinopathy. Beta-glucogallin and other Amla bioactives inhibit aldose reductase, addressing this damaging pathway. Mechanism complements direct glucose-lowering effects.
Polyphenol antioxidant activity
Amla contains numerous phytoconstituents — polyphenols, tannins, gallic acid, ellagic acid, amino acids, vitamins, minerals, fixed oils, and flavonoids. The polyphenols, tannins, and flavonoids play key roles in most of E. officinalis bioactivities. Antioxidant activity supports metabolic health alongside the broader anti-aging traditional Ayurvedic positioning.
Anti-inflammatory effects
Amla bioactives have documented anti-inflammatory effects across multiple cellular models. Chronic low-grade inflammation drives metabolic syndrome and diabetic complications. Reducing inflammation supports comprehensive metabolic health beyond pure glucose/lipid markers.
Antioxidant enzyme upregulation
Amla helps maintain anti-oxidant enzyme levels in the system — supporting endogenous antioxidant defense beyond direct antioxidant scavenging. The mechanism is more physiologically sustainable than single-molecule antioxidant supplementation (which can saturate). Upregulated antioxidant enzymes provide sustained cellular protection.
Clinical trials
90-day multicentric randomized open-label clinical trial comparing two doses of Saberry (1 g and 2 g/day) with metformin 500 mg/day in newly-diagnosed Type 2 diabetics with dyslipidemia. Three-arm design. Outcomes: fasting blood sugar (FBS), post-prandial blood sugar (PPBS), HbA1c, lipid profile, safety parameters. Published in Food & Function (2022;13:9523-31).
124 newly diagnosed Type 2 diabetic subjects aged 30-65 with diabetic dyslipidemia (a diagnosed-disease population), randomized across three arms for 90 days in an open-label, manufacturer-affiliated design.
Both Saberry doses produced dose-dependent improvements in glucose and lipid metabolism. 2 g/day produced 21.8% fasting blood sugar reduction vs 14.6% with 1 g/day. Numerically the 2 g dose showed a larger fasting-glucose fall than metformin 500 mg, but because the trial was open-label (not blinded) and manufacturer-run, this cannot be read as Saberry outperforming metformin. Significant improvements in total cholesterol, LDL, VLDL, triglycerides, HbA1c, and post-prandial blood sugar. Safe and well-tolerated.
Preclinical and in vitro mechanistic studies on Saberry's beta-glucogallin bioactivity, including aldose reductase inhibition (relevant for diabetic complications) and antioxidant pathway modulation. Foundation for the human clinical trial findings.
Not applicable — in vitro and preclinical mechanistic studies.
Beta-glucogallin demonstrated aldose reductase inhibition and antioxidant pathway activation. This is a proposed preclinical mechanism; it does not by itself establish the clinical glucose or lipid effects. The standardization to beta-glucogallin (vs generic tannins or vitamin C) is supported by the mechanistic data — beta-glucogallin is the key bioactive driving the metabolic effects.
Class evidence for Emblica officinalis (Amla) across traditional Ayurvedic use spanning thousands of years and modern preclinical/clinical research. Amla has been used extensively in digestive support and immune applications. Numerous studies of various Amla extracts for diabetes, cholesterol, and antioxidant outcomes.
Various — adults across traditional Ayurvedic use and modern Amla research base.
Amla consistently demonstrates antioxidant, anti-inflammatory, and metabolic health effects. Long traditional use precedent supports broad safety profile. Saberry's beta-glucogallin standardization distinguishes from other Amla products that may have less reproducible bioactivity. Self-affirmed GRAS supports the safety positioning of standardized extracts.